Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adebrelimab (Primary) ; BAT 8003 (Primary) ; Camrelizumab (Primary) ; Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Dalpiciclib (Primary) ; Epirubicin (Primary) ; Fuzuloparib (Primary) ; Goserelin (Primary) ; Letrozole (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Pyrotinib (Primary) ; Trastuzumab (Primary) ; Trastuzumab rezetecan (Primary)
Indications Breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms FASCINATE-N

27 Dec 2024 Planned primary completion date changed from 1 Sep 2024 to 31 Dec 2024.
13 Dec 2024 Study design were presented at the 47th Annual San Antonio Breast Cancer Symposium.
03 Feb 2023 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com